<DOC>
	<DOCNO>NCT01710709</DOCNO>
	<brief_summary>This open-label uncontrolled trial evaluate safety tolerability aripiprazole IM depot administer every 4 week 52 week patient bipolar I disorder . The trial enroll subject complete Trial 31-08-250 de novo subject participate Trial 31-08-250 .</brief_summary>
	<brief_title>Open-label Study Evaluate Effectiveness Intramuscular Formulation Aripiprazole ( OPC-14597 ) Maintenance Treatment Patients With Bipolar I Disorder</brief_title>
	<detailed_description>This open-label , uncontrolled study enroll completers Study 31-08-250 new subject participate Studies 250 . The treatment history subject prior enrolment open-label study vary accord design pivotal double-blind study ( i.e 31-08-250 ) . This open-label study comprise phase similar pivotal double-blind study ( i.e . Study 250 ) : screening phase ( applicable ) , conversion phase ( Phase A , applicable ) , oral stabilization phase ( Phase B , applicable ) , IM depot open-label maintenance phase ( Phase C ) . Phase C minimum 28 week 52-week treatment period 4 week follow period . During Phase C ( open-label maintenance phase ) rescue medication allow subject meet stability criterion .</detailed_description>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Completed participation Trial 3108250 De novo subject participate Trial 3108250 Subjects able provide write informed consent . Male female subject 18 year age old time inform consent Subjects , investigator 's judgment , require chronic treatment antipsychotic medication bipolar I disorder would benefit extended treatment longacting injectable formulation Subjects recurrence mood episode exacerbation mood symptom receive treatment bipolar I disorder noncompliant treatment bipolar I disorder Have outpatient status Experienced 9 mood episode within past year A current manic episode duration &gt; 2 year Currently meet DSMIVTR criterion substance abuse substance dependence ; include abuse alcohol benzodiazepine , excludes use caffeine and/or nicotine Hypothyroidism hyperthyroidism , unless condition stabilize Diagnosed epilepsy history seizure Known allergic , intolerant , unresponsive prior treatment aripiprazole quinolinones Sexually active woman childbearing potential sexually active men commit utilize 2 approved birth control method remain abstinent trial 180 day follow last dose trial medication Females breastfeeding pregnant ( positive blood pregnancy test prior receive trial drug ) Risk commit suicide Abnormal laboratory test result , vital sign ECG result Participated clinical trial Trial 250 investigational agent within 30 day prior screen Had electroconvulsive therapy ( ECT ) treatment current episode within 3 month Subjects meet criterion stabilization 4 consecutive week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Aripiprazole , Intramuscular ( IM ) Depot , Bipolar</keyword>
</DOC>